Wolff Wiese Magana LLC Buys 3,776 Shares of Boston Scientific Corporation (NYSE:BSX)

Wolff Wiese Magana LLC increased its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 121.0% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,896 shares of the medical equipment provider's stock after acquiring an additional 3,776 shares during the period. Wolff Wiese Magana LLC's holdings in Boston Scientific were worth $696,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Investment Management Corp VA ADV bought a new stake in Boston Scientific during the fourth quarter worth about $25,000. Colonial Trust Co SC raised its holdings in Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 260 shares in the last quarter. Sunbeam Capital Management LLC bought a new stake in Boston Scientific during the fourth quarter worth about $26,000. Ameriflex Group Inc. bought a new stake in Boston Scientific during the fourth quarter worth about $31,000. Finally, Fairway Wealth LLC bought a new stake in Boston Scientific during the fourth quarter worth about $36,000. Institutional investors own 89.07% of the company's stock.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,314 shares of the firm's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total value of $1,767,066.84. Following the sale, the executive vice president now owns 22,235 shares of the company's stock, valued at approximately $2,269,304.10. This trade represents a 43.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the firm's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total value of $5,799,551.36. Following the completion of the sale, the executive vice president now directly owns 178,342 shares in the company, valued at approximately $18,347,824.96. This represents a 24.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 411,970 shares of company stock valued at $42,406,693 over the last 90 days. 0.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on BSX. Needham & Company LLC reiterated a "buy" rating and set a $115.00 target price on shares of Boston Scientific in a report on Wednesday, May 28th. Wall Street Zen upgraded Boston Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, April 29th. BTIG Research restated a "buy" rating and issued a $124.00 price objective on shares of Boston Scientific in a research note on Wednesday, April 23rd. Truist Financial upped their price objective on Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a research note on Thursday, April 24th. Finally, Robert W. Baird upped their price objective on Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Twenty-two research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $116.09.

Boston Scientific Trading Down 0.0%

Shares of NYSE:BSX opened at $101.35 on Friday. The company has a market capitalization of $149.94 billion, a P/E ratio of 73.98, a P/E/G ratio of 2.62 and a beta of 0.68. Boston Scientific Corporation has a 1 year low of $71.88 and a 1 year high of $107.17. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88. The business's 50 day simple moving average is $101.77 and its 200 day simple moving average is $99.11.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The business had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The firm's quarterly revenue was up 20.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.56 earnings per share. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.